[Skip to content]

European Parkinson's Disease Association
Search our Site



Medication research papers

  • PlosONE Bee Venom for the Treatment of Parkinson Disease A Randomized Controlled Clinical TrialThis study did not evidence any clear symptomatic or disease-modifying effects of monthly bee venom injections over an 11 month period compared to placebo using a standard bee venom allergy desensitization protocol in Parkinson disease patients. However, bee venom administration appeared safe in non-allergic subjects. Thus, authors suggest that higher administration frequency and possibly higher individual doses of bee venom may reveal its potency in treating Parkinson disease. 12 July 2016
  • Journal of Parkinson's Disease Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodiesThis small proof-of-concept study lacks a placebo group and participants were not homogenous, resulting in baseline differences between and within groups. This limits the interpretations of the biomarker and clinical data, and any conclusions should be drawn cautiously. Nonetheless, the collective observations suggest that it is warranted to evaluate the safety and efficacy of Nilotinib in larger randomized, double-blind, placebo-controlled trials. 11 July 2016
  • Planta Medica Medicinal Plants and Natural Products as Potential Sources for Antiparkinson DrugsIn this review, authors have compiled data on the principal medicinal plants and natural products as potential antiparkinsonian agents. They act by different mechanisms, such as the inhibition of α-synuclein condensation, reduction of oxidative stress and neuro-inflammation, increase of dopaminergic neurons survival, or the blockade of the A2 A receptor. 01 July 2016
  • Neurotherapeutics Volume 8 Issue 4 hVMAT2: A Target of Individualized Medication for Parkinson's DiseaseBased on human genetic association and meta-analysis, authors first confirm the human VMAT2 (hVMAT2 or SLC18A2) promoter as a risk factor for PD in both family and unrelated US white people: marker rs363324 at 11.5 kb in the hVMAT2 promoter is reproducibly associated with PD in a cohort of nuclear families (p = 0.04506 in early-onset PD) and 3 unrelated US white people (meta-analysis p = 0.01879). 01 July 2016
  • Parkinsonism & Related Disorders Volume 27 Use of antidepressants in Parkinson's disease: A Swedish register-based study of over 1.5 million older peopleResults: Twenty-two percent of the home-dwellers and 50% of the institutionalized elderly persons with APD used antidepressants. Persons with APD had a higher probability of use of any antidepressant compared to persons without APD. A selective serotonin reuptake inhibitor (SSRI) was the most commonly used antidepressants in both settings followed by mirtazapin. 01 June 2016
  • Journal of Neurology Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort studyOPTIPUMP was a prospective, open-label, observational cohort study involving 30 investigational sites in France. CSAI was proposed as part of routine clinical care to patients aged 18 years, in absence of dementia, with a PD diagnosis and based on the presence of motor fluctuations not controlled by oral treatments. 01 June 2016
  • Parkinsonism & Related Disorders Volume 27 Pharmacological Interventions for Daytime Sleepiness and Sleep Disorders in Parkinson's: Systematic Review and Meta-AnalysisConclusions: Whilst providing recommendations, this systematic review depicts the lack of a clear body of evidence for treating sleep disorders in PD patients; hence, further studies are warranted. 01 June 2016
  • Parkinsonism & Related Disorders Volume 28 Levodopa responsiveness of dysphagia in advanced Parkinson's disease and reliability testing of the FEES-Levodopa-testConclusions: A significant proportion of advanced PD patients with motor fluctuations and mild to moderate oropharyngeal dysphagia may demonstrate a clinically relevant improvement of swallowing after levodopa challenge. The FEES-levodopa-test is a reliable and sensitive tool to differentiate these responders from non-responders. 01 June 2016
  • Parkinsonism & Related Disorders Volume 27 Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibitionResults: The prevalence of neuropathy in LELD patients was 19.4% whereas it was 5.7% in LELD_ICOMT group with a significant difference (p = 0.025). In LELD_ICOMT cohort the daily LD dose and serum VB12 levels were significantly higher (p < 0.0001), the serum Hcy levels were significantly lower (p = 0.001) compared to LELD group. 01 June 2016
  • Parkinsonism & Related Disorders Volume 27 Gender and non motor fluctuations in Parkinson's disease: A prospective studyThe study showed that female gender represents a major risk factor for the development of NMF. There were no gender differences in medication intake, thus NMF in women remain mostly underestimated and not properly treated. From a practical standpoint, clinicians should take into account the role of gender in the management of NMF in PD. 01 June 2016
Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]